NasdaqCM:CASM

Stock Analysis Report

Executive Summary

CAS Medical Systems, Inc., a medical technology company, develops, manufactures, and markets non-invasive patient monitoring products worldwide.

Snowflake

Fundamentals

Slightly overvalued with concerning outlook.

Risks

  • CAS Medical Systems has significant price volatility in the past 3 months.
  • CAS Medical Systems is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has CAS Medical Systems's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.8%

CASM

1.1%

US Medical Equipment

-0.5%

US Market


1 Year Return

105.9%

CASM

7.9%

US Medical Equipment

0.9%

US Market

CASM outperformed the Medical Equipment industry which returned 16.2% over the past year.

CASM outperformed the Market in United States of America which returned 5.9% over the past year.


Share holder returns

CASMIndustryMarket
7 Day0.8%1.1%-0.5%
30 Day0.8%3.1%4.8%
90 Day26.1%3.6%2.3%
1 Year105.9%105.9%8.8%7.9%3.1%0.9%
3 Year28.3%28.3%70.9%65.8%45.5%36.0%
5 Year8.9%8.9%139.2%112.0%62.5%44.7%

Price Volatility Vs. Market

How volatile is CAS Medical Systems's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is CAS Medical Systems undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

CAS Medical Systems's share price is below the future cash flow value, and at a moderate discount (> 20%).

CAS Medical Systems's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

CAS Medical Systems is loss making, we can't compare its value to the US Medical Equipment industry average.

CAS Medical Systems is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for CAS Medical Systems, we can't assess if its growth is good value.


Price Based on Value of Assets

CAS Medical Systems has negative assets, we can't compare the value of its assets to the US Medical Equipment industry average.


Next Steps

Future Growth

How is CAS Medical Systems expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

18.3%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

CAS Medical Systems's revenue is expected to grow by 18.3% yearly, however this is not considered high growth (20% yearly).

Unable to determine if CAS Medical Systems is high growth as no earnings estimate data is available.

CAS Medical Systems's revenue growth is expected to exceed the United States of America market average.

Unable to compare CAS Medical Systems's earnings growth to the United States of America market average as no estimate data is available.

Unable to compare CAS Medical Systems's earnings growth to the low risk savings rate as no estimate data is available.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if CAS Medical Systems will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has CAS Medical Systems performed over the past 5 years?

9.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

CAS Medical Systems does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare CAS Medical Systems's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare CAS Medical Systems's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if CAS Medical Systems has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if CAS Medical Systems has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if CAS Medical Systems improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is CAS Medical Systems's financial position?


Financial Position Analysis

CAS Medical Systems is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

CAS Medical Systems's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

CAS Medical Systems has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if CAS Medical Systems's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

CAS Medical Systems has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

CAS Medical Systems has less than a year of cash runway based on current free cash flow.

CAS Medical Systems has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.3% each year.


Next Steps

Dividend

What is CAS Medical Systems's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate CAS Medical Systems's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate CAS Medical Systems's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as CAS Medical Systems has not reported any payouts.

Unable to verify if CAS Medical Systems's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as CAS Medical Systems has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of CAS Medical Systems's salary, the management and board of directors tenure and is there insider trading?

8.7yrs

Average management tenure


CEO

Tom Patton (54yo)

8.7yrs

Tenure

US$758,704

Compensation

Mr. Thomas M. Patton, also known as Tom, J.D. has been the President and Chief Executive Officer of CAS Medical Systems, Inc. since August 27, 2010. Mr. Patton joined the CAS on August 27, 2010. He serves  ...


CEO Compensation Analysis

Tom's remuneration is higher than average for companies of similar size in United States of America.

Tom's compensation has increased whilst company is loss making.


Management Age and Tenure

8.7yrs

Average Tenure

55yo

Average Age

The average tenure for the CAS Medical Systems management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

7.8yrs

Average Tenure

57yo

Average Age

The tenure for the CAS Medical Systems board of directors is about average.


Insider Trading

No 3 month insider trading information.


Recent Insider Transactions

SellUS$155,46222 Apr 19
James Thomas
EntityIndividual
Role
Lead Director
Lead Director
Shares63,454
Max PriceUS$2.45
SellUS$30,588,14222 Apr 19
Thomas, McNerney & Partners
EntityCompany
Shares12,484,956
Max PriceUS$2.45
SellUS$2,280,67822 Apr 19
Thomas Patton
EntityIndividual
Role
Chief Executive Officer
President
Shares1,080,889
Max PriceUS$2.45

Ownership Breakdown


Management Team

  • Tom Patton (54yo)

    President

    • Tenure: 8.7yrs
    • Compensation: US$758.70k
  • Jeffery Baird (64yo)

    CFO & Secretary

    • Tenure: 15.3yrs
    • Compensation: US$385.66k
  • Karen Harris-Coleman (56yo)

    Executive Vice President of International Sales

    • Tenure: 5.1yrs
  • Susan Carron

    Director of Corporate Communications

    • Tenure: 0yrs
  • Kim Strusky

    Executive Vice President of U.S. Sales

    • Tenure: 3.5yrs
  • Paul Benni (50yo)

    Chief Scientific Officer

    • Tenure: 13.3yrs

Board Members

  • Tom Patton (54yo)

    President

    • Tenure: 8.7yrs
    • Compensation: US$758.70k
  • Alan Milinazzo (58yo)

    Director

    • Tenure: 3.8yrs
    • Compensation: US$55.65k
  • James Thomas (57yo)

    Lead Director

    • Tenure: 7yrs
    • Compensation: US$55.65k
  • Paul Molloy (56yo)

    Director

    • Tenure: 4.3yrs
    • Compensation: US$55.65k
  • Ken Weisshaar (67yo)

    Director

    • Tenure: 9yrs
    • Compensation: US$60.65k
  • Kathy Tune (53yo)

    Director

    • Tenure: 7.8yrs
    • Compensation: US$55.65k
  • Greg Rainey (65yo)

    Director

    • Tenure: 8.5yrs
    • Compensation: US$55.65k

Company Information

CAS Medical Systems, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: CAS Medical Systems, Inc.
  • Ticker: CASM
  • Exchange: NasdaqCM
  • Founded: 1984
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$68.728m
  • Shares outstanding: 28.05m
  • Website: https://www.fore-sight.com

Number of Employees


Location

  • CAS Medical Systems, Inc.
  • 44 East Industrial Road
  • Branford
  • Connecticut
  • 6405
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CASMNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDSep 1985
UM1DB (Deutsche Boerse AG)YesCommon StockDEEURSep 1985

Biography

CAS Medical Systems, Inc., a medical technology company, develops, manufactures, and markets non-invasive patient monitoring products worldwide. The company provides FORE-SIGHT tissue oximeter monitors, se ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/04/18 23:32
End of Day Share Price2019/04/18 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.